Core Viewpoint - The company has decided to terminate part of its fundraising projects and delay others, based on a careful assessment of the current market conditions and project progress, ensuring that these decisions align with the long-term interests of the company and its shareholders [1][10]. Fundraising Overview - The company raised a net amount of RMB 1,002,572,682.71 through its initial public offering, verified by an accounting firm [1]. - The company has established a management system for the use of raised funds, ensuring that funds are stored in dedicated accounts and used strictly for their intended purposes [2]. Termination of Fundraising Projects - The project "Zihang Medical Device Component Intelligent Manufacturing and Expansion Project" will be terminated, with the total investment amount reduced from RMB 282.84 million to RMB 143.47 million, and the fundraising investment amount decreased from RMB 282.84 million to RMB 135.77 million [3]. - The termination is influenced by changes in market demand and increased competition, leading to a reassessment of the project's viability [6][7]. Reasons for Project Termination - The implementation of centralized procurement policies has created volatility in market demand, affecting the sales cycle and capacity planning for the project [6]. - The existing production capacity is deemed sufficient to meet current demand, and further investment could lead to idle capacity risks [7]. Impact of Project Termination - The termination is expected to enhance the efficiency of fundraising usage and will not adversely affect the company's normal operations or shareholder interests [8]. - The remaining funds from the terminated project will be retained in dedicated accounts for future investment opportunities [8]. Delay of Fundraising Projects - The "Weike Medical Minimally Invasive Surgical New Product Project" will be delayed, with the expected completion date pushed from June 30, 2025, to December 31, 2027 [9]. - The delay is attributed to changes in market conditions and the need for further product development to meet diverse customer needs [9]. Reasons for Project Delay - The company is adapting to market changes and enhancing product features through increased R&D investment, which has necessitated a phased approach to project implementation [9]. - The execution of procurement policies has affected the expected market release timeline for the company's products [9]. Impact of Project Delay - The delay is a strategic decision that does not involve changes to the project’s implementation structure or total investment, ensuring that it aligns with the company's long-term development goals [9][10].

证券代码：301290 证券简称：东星医疗 江苏东星智慧医疗科技股份有限公司 投资者关系活动记录表 编号：2025-001 2.从地域来看，公司在华北地区营收增长 30.11%，而在华 南、东北等地区却出现下滑。是什么因素导致的？公司针对不 同地区的市场策略有何调整计划？ 答:尊敬的投资者，您好！2024年度，公司华北地区营收增 长原因主要是京津冀"3+N"联盟带量采购政策的执行后，通过 集采协议推动区域市场覆盖，公司针对性开展重点客户开发， 新增客户资源，叠加市场拓展及客户需求增加的双重作用。未 来，公司将进一步深入分析政策环境、客户需求及竞争格局差 异，针对性调整资源配置，强化客户关系管理，提升区域品牌 渗透率。感谢您的关注！ 3.贵司目前布局合成生物领域做了哪些举措？ 答:尊敬的投资者，您好！公司在科技战略规划中加快布局 合成生物领域，快速推进重组人源化胶原蛋白、贻贝粘蛋白等 产品的研发；在战略重构规划中积极拓展合成生物领域。公司 于2025年3月与常州大学签署捐赠协议，联合开办"东星医疗— 合成生物学创新班"，公司向常州大学捐赠100万元，专项支持 合成生物学创新班建设发展。未来，东星医疗将通过设立奖 ...